The document outlines the procedure for the formulary placement of newly FDA-approved innovator drugs within the TRICARE Pharmacy Benefits Program, as established by the Final Rule published on July 27, 2015. It grants the Pharmacy and Therapeutics (P&T) Committee up to 120 days to recommend tier placements for these drugs, which include various types of new molecular entities and formulations. Innovator drugs approved on or after August 26, 2015, will initially receive pending status and will be subject to evaluations at quarterly meetings, where their cost-effectiveness will also be assessed. The DHA Director has the final authority on formulary recommendations. Additionally, these drugs could be classified as Tier 3 and therefore may not be accessible at Military Treatment Facilities unless medically necessary or available at higher copays through retail or TMOP channels. The document emphasizes the limited capacity for clinical presentations due to the high volume of approvals and instructs pharmaceutical manufacturers regarding Distribution and Pricing Agreements, impacting their participation in the formulary system. This initiative highlights the government's focus on balancing healthcare accessibility with financial prudence in managing innovative pharmaceuticals.

The Price Appendix FAQ outlines the procedures for submitting quotes for drug pricing associated with the federal government's formulary system. It emphasizes the need for vendors to carefully review the Formulary Notes for insights into the P&T committee's criteria for formulary status. Vendors are required to fill in designated yellow cells in provided tables for up to 10 National Drug Codes (NDCs), with auto-population features for specific pricing columns to streamline the process. The document addresses three pricing models: BPA, ADP (non-FAMP Discount), and ADP (WAC Discount). Each section details instructions on entering prices and conditions for products, along with what actions result in visual notifications (e.g., highlighting in red). If more than 10 NDCs need to be submitted, vendors must reach out for additional tables. The FAQ underscores the importance of clear communication with Points of Contact if there are questions or issues, ensuring a compliant and efficient submission process. This document is vital in managing the pricing submissions for pharmaceutical products within the context of federal requests for proposals and grants, thus contributing to effective government procurement practices.

The document outlines the upcoming Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee Meeting scheduled for May 7-8, 2025, focusing on the Uniform Formulary Class of Pain Agents, specifically within the Pain Miscellaneous subclass. Quotes for newly approved drugs are due by March 20, 2025. Each drug under consideration is categorized as either Uniform or Non-Formulary, with various scenarios laid out to guide potential quotations. The document emphasizes the potential for prior authorization, preferential status for select non-generic drugs treated as generics (Tier 1), and the consideration of special reimbursement methods. Additionally, manufacturers are reminded to submit fully executed signature pages alongside their quotes. This meeting serves to evaluate pharmaceutical agents for TRICARE, ensuring effective management of drug formulary listings. The ongoing review process aims to optimize drug selection for military treatment facilities and mail-order services, ensuring that high-value pharmaceutical products are prioritized while discouraging lower-value alternatives, reflecting the DoD's commitment to enhancing healthcare benefits for service members.

The document outlines a series of Blanket Purchase Agreements and Additional Discount Programs related to newly approved antiviral drugs under the Department of Defense (DoD) Uniform Formulary. Key events include the upcoming Pharmacy and Therapeutics (P&T) Committee meeting scheduled for May 7-8, 2025, with a deadline for quote submissions set for March 20, 2025. The document specifies unique identifiers (NDC Numbers) for the drugs, alongside their formulary status (Uniform or Non-Formulary), with notes about potential pricing scenarios and conditions. It emphasizes the importance of quoting accurately and adhering to prior authorization requirements, as well as encouraging the use of high-value products through specified pricing methodologies. Additionally, the document instructs manufacturers to submit completed signature pages with their quote information. This structure aids in the evaluation of antiviral agents, ensuring that cost-effective and clinically valuable drugs are prioritized in the DoD's pharmacy benefits program, while also hinting at the strategic intention to influence prescribing behaviors within military treatment facilities.

The document outlines the Department of Defense (DOD) Uniform Formulary updates regarding targeted immunomodulatory biologics, specifically interleukin-23 agents, with a focus on a Pharmaceutical and Therapeutics (P&T) Committee Meeting scheduled for May 7-8, 2025. Manufacturers are instructed to submit quotes for newly approved drugs by March 20, 2025, with details regarding various agents and pricing structures provided. Prior Authorization (PA) protocols may apply, with potential for agents to be considered for preferential status based on economic factors and patient health outcomes. The document emphasizes the importance of step therapy, wherein patients may need to demonstrate a trial of preferrred agents before accessing certain medications. It includes guidelines for formulary categories, pricing calculations, and conditions for refunds as part of the TRICARE program. Manufacturers are reminded to include all necessary documents, including executed signatures, with their submissions. This structure aims to ensure consistent cost control and promote effective pharmaceutical practices within the DOD healthcare system.

The document discusses an upcoming meeting of the Department of Defense (DOD) Pharmacy and Therapeutics (P&T) Committee scheduled for May 7-8, 2025, focusing on the approval process for Targeted Immunomodulatory Biologics, specifically within the subclass of Interleukin 23. It outlines the requirements for drug quotes due by March 20, 2025, emphasizing the need for manufacturers to submit fully executed signature pages along with their quotations. The document extensively details various scenarios for blanket purchase agreements related to newly approved drugs, including pricing formats and conditions for drug classification, such as step therapy protocols. It also highlights potential strategies for cost management, including special reimbursement methods to encourage the use of high-value products while dissuading low-value alternatives. The P&T Committee may suggest preferential statuses for certain pharmaceutical agents and their exclusion from the pharmacy benefit program. Additionally, it addresses the implications of prior authorization processes to assess effectiveness before prescribing specific non-step-preferred agents and notes the importance of rigorous adherence to drug pricing guidelines relevant to federal ceiling prices and retail refunds across military treatment facilities. This structured approach underscores the DOD's commitment to optimizing drug formularies for military healthcare.

The document outlines the upcoming Department of Defense (DOD) Pharmacy and Therapeutics (P&T) Committee meeting scheduled for May 7-8, 2025, focusing on the evaluation of newly approved drugs within the subclass of targeted immunomodulatory biologics, specifically interleukin 23. Bids for drug pricing are due by March 20, 2025, with no quotes submitted for the listed NDC numbers under several blanket purchase agreements. Key considerations include a structured prior authorization process, which mandates that new patients complete trial treatments with preferred agents before accessing non-preferred options across multiple service venues, including Military Treatment Facilities (MTFs) and retail pharmacies. The DOD P&T Committee may reevaluate existing step therapy preferences and consider designating agents without received quotes as non-preferred. Additionally, the document emphasizes the importance of manufacturers submitting necessary documentation alongside pricing proposals. In conclusion, this meeting demonstrates DOD's systematic approach to managing pharmaceutical reimbursements and ensuring high-value treatments for beneficiaries while addressing compliance and effectiveness in drug formulary management.

The Department of Defense (DOD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be considered for placement on the Uniform Formulary (UF) under the Defense Health Agency (DHA). This process involves the Pharmacy and Therapeutics (P&T) Committee evaluating the clinical and cost-effectiveness of medications before recommending them for TRICARE's pharmacy benefit. Manufacturers may submit discount and blanket purchase agreement quotes, which will be assessed during the P&T Committee meeting. Key components include submission guidelines, the evaluation criteria, and necessary documentation such as the NDC Price List and Manufacturer Quote Submission Checklist. The submission includes two types of quotes: the UF Blanket Purchase Agreement (UF BPA) for Military Treatment Facilities (MTFs) and TRICARE Mail Order Pharmacy (TMOP), and the Uniform Formulary Additional Discount Program (UF ADP) for the TRICARE retail network. Manufacturers are urged to provide detailed descriptions of drug benefits, clinical efficacy and expected outcomes. The successful candidates will be contracted based on the recommendations of the P&T Committee, considering not only pricing but also the formulary classification of each agent. Overall, this RFQ represents the DOD's commitment to providing effective pharmaceutical solutions for military healthcare while optimizing costs.